Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022
Curis focuses its resources to drive the development of emavusertib
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.